RxNorm 977427

everolimus 0.25 MG Oral Tablet

RxNorm Semantic Concepts

RxNorm semantic concepts for the RxCUI 977427 unique identifier include: everolimus 0.25 MG Oral Tablet (6362888), everolimus 0.25 MG Oral Tablet (3086106), Everolimus 250 microgram oral tablet (10298398) and Product containing precisely everolimus 250 microgram/1 each conventional release oral tablet (clinical drug) (10312367).

RxNorm Atom ID: 6362888 - Prescribable Name
everolimus 0.25 MG Oral Tablet

RXCUI:
977427 - RxNorm Unique Identifier for a concept (Concept ID)
LAT:
ENG - Language of the Term
RXAUI:
6362888 - Unique identifier for the atom (RxNorm Atom ID)
Is Prescribable?
YES - This drug is part of the RxNorm Current Prescribable Content, a subset of RxNorm that includes all drugs available for prescription in the United States. The Current Prescribable subset also includes over-the-counter drugs.
Concept Description:
everolimus 0.25 MG Oral Tablet - Description of concept identifier
Term Type (TTY):
PSN - Term type in source with name and description
Term Type Name:
Prescribable Name - Name of term type in source
Term Type Description:
Synonym of another TTY, given for clarity and for display purposes in electronic prescribing applications. Only one PSN per concept. - Description of term type in source
Code:
977427 - "Most useful" source asserted identifier. If the source vocabulary has more than one identifier, or a RxNorm-generated source entry identifier. (if the source vocabulary has none.)
Suppress Flag:
N
Suppressible flag. Values = N, O, Y, or E. N - not suppressible. O - Specific individual names (atoms) set as Obsolete because the name is no longer provided by the original source. Y - Suppressed by RxNorm editor. E - unquantified, non-prescribable drug with related quantified, prescribable drugs. NLM strongly recommends that users not alter editor-assigned suppressibility.
CVF:
4096 - Content view flag. RxNorm includes one value, '4096', to denote inclusion in the Current Prescribable Content subset. All rows with CVF='4096' can be found in the subset.
Source:
RXNORM - Concept source abbreviation
Source Name:
RxNorm Vocabulary - The official name for a source
Source Version:
20AA_240304F - The source version
Source Date:
March 04, 2024 - RxNorm data last updated
Source License Contact:
RxNorm Customer Service

U.S. National Library of Medicine
8600 Rockville Pike

Bethesda
MD
United States
20894
(888) FIND-NLM

[email protected]
https://www.nlm.nih.gov/research/umls/rxnorm/ - The source license contact information
Source Content Contact:
RxNorm Customer Service

U.S. National Library of Medicine
8600 Rockville Pike

Bethesda
MD
United States
20894
(888) FIND-NLM

[email protected]
https://www.nlm.nih.gov/research/umls/rxnorm/ - The source content contact information
Source Short Name:
RxNorm work done by the National Library of Medicine - The short name of a source as used by the NLM Knowledge Source Server

RxNorm Atom ID: 3086106 - Semantic Clinical Drug
everolimus 0.25 MG Oral Tablet

RXCUI:
977427 - RxNorm Unique Identifier for a concept (Concept ID)
LAT:
ENG - Language of the Term
RXAUI:
3086106 - Unique identifier for the atom (RxNorm Atom ID)
Is Prescribable?
YES - This drug is part of the RxNorm Current Prescribable Content, a subset of RxNorm that includes all drugs available for prescription in the United States. The Current Prescribable subset also includes over-the-counter drugs.
Concept Description:
everolimus 0.25 MG Oral Tablet - Description of concept identifier
Term Type (TTY):
SCD - Term type in source with name and description
Term Type Name:
Semantic Clinical Drug - Name of term type in source
Term Type Description:
Ingredient + Strength + Dose Form - Description of term type in source
Code:
977427 - "Most useful" source asserted identifier. If the source vocabulary has more than one identifier, or a RxNorm-generated source entry identifier. (if the source vocabulary has none.)
Suppress Flag:
N
Suppressible flag. Values = N, O, Y, or E. N - not suppressible. O - Specific individual names (atoms) set as Obsolete because the name is no longer provided by the original source. Y - Suppressed by RxNorm editor. E - unquantified, non-prescribable drug with related quantified, prescribable drugs. NLM strongly recommends that users not alter editor-assigned suppressibility.
CVF:
4096 - Content view flag. RxNorm includes one value, '4096', to denote inclusion in the Current Prescribable Content subset. All rows with CVF='4096' can be found in the subset.
Source:
RXNORM - Concept source abbreviation
Source Name:
RxNorm Vocabulary - The official name for a source
Source Version:
20AA_240304F - The source version
Source Date:
March 04, 2024 - RxNorm data last updated
Source License Contact:
RxNorm Customer Service

U.S. National Library of Medicine
8600 Rockville Pike

Bethesda
MD
United States
20894
(888) FIND-NLM

[email protected]
https://www.nlm.nih.gov/research/umls/rxnorm/ - The source license contact information
Source Content Contact:
RxNorm Customer Service

U.S. National Library of Medicine
8600 Rockville Pike

Bethesda
MD
United States
20894
(888) FIND-NLM

[email protected]
https://www.nlm.nih.gov/research/umls/rxnorm/ - The source content contact information
Source Short Name:
RxNorm work done by the National Library of Medicine - The short name of a source as used by the NLM Knowledge Source Server

RxNorm Atom 3086106 Attributes

PropertyValueExplanation
RXN AI{977426} 141704RXCUI of BOSS Active Ingredient preceded by RXCUI of SCDC responsible for value
RXN AM{977426} 141704RXCUI of BOSS Active Moiety preceded by RXCUI of SCDC responsible for value
RXN AVAILABLE STRENGTH0.25 MGAvailable drug strengths listed in the order of ingredients from the drug
RXN BOSS FROM{977426} AISource of BOSS as either from the active ingredient (AI) or the active moiety (AM) preceded by RXCUI of SCDC responsible for value
RXN HUMAN DRUGUSDrug available for use in Humans
RXTERM FORMTabThe RxTerm dose form name for this drug

RxNorm Atom ID: 10298398 - Designated preferred name
Everolimus 250 microgram oral tablet

RXCUI:
977427 - RxNorm Unique Identifier for a concept (Concept ID)
LAT:
ENG - Language of the Term
RXAUI:
10298398 - Unique identifier for the atom (RxNorm Atom ID)
Is Prescribable?
YES - This drug is part of the RxNorm Current Prescribable Content, a subset of RxNorm that includes all drugs available for prescription in the United States. The Current Prescribable subset also includes over-the-counter drugs.
Concept Description:
Everolimus 250 microgram oral tablet - Description of concept identifier
Term Type (TTY):
PT - Term type in source with name and description
Term Type Name:
Designated preferred name - Name of term type in source
Term Type Description:
- Description of term type in source
Code:
447132004 - "Most useful" source asserted identifier. If the source vocabulary has more than one identifier, or a RxNorm-generated source entry identifier. (if the source vocabulary has none.)
Suppress Flag:
N
Suppressible flag. Values = N, O, Y, or E. N - not suppressible. O - Specific individual names (atoms) set as Obsolete because the name is no longer provided by the original source. Y - Suppressed by RxNorm editor. E - unquantified, non-prescribable drug with related quantified, prescribable drugs. NLM strongly recommends that users not alter editor-assigned suppressibility.
CVF:
- Content view flag. RxNorm includes one value, '4096', to denote inclusion in the Current Prescribable Content subset. All rows with CVF='4096' can be found in the subset.
Source:
SNOMEDCT_US - Concept source abbreviation
Source Name:
US Edition of SNOMED CT - The official name for a source
Source Version:
2024_01_01 - The source version
Source Date:
March 04, 2024 - RxNorm data last updated
Source License Contact:
National Library Of Medicine
NLM is a Charter Member of SNOMED International on behalf of the U.S.
National Library of Medicine
8600 Rockville Pike

Bethesda
MD
United States
20894
1-888-FIND-NLM (1-888-346-3656)

https://support.nlm.nih.gov/support/create-case/
- The source license contact information
Source Content Contact:
National Library Of Medicine
NLM is a Charter Member of SNOMED International on behalf of the U.S.
National Library Of Medicine
8600 Rockville Pike

Bethesda
MD
United States
20894
1-888-FIND-NLM (1-888-346-3656)

https://support.nlm.nih.gov/support/create-case/
- The source content contact information
Source Short Name:
US Edition of SNOMED CT - The short name of a source as used by the NLM Knowledge Source Server

RxNorm Atom ID: 10312367 - Full form of descriptor
Product containing precisely everolimus 250 microgram/1 each conventional release oral tablet (clinical drug)

RXCUI:
977427 - RxNorm Unique Identifier for a concept (Concept ID)
LAT:
ENG - Language of the Term
RXAUI:
10312367 - Unique identifier for the atom (RxNorm Atom ID)
Is Prescribable?
YES - This drug is part of the RxNorm Current Prescribable Content, a subset of RxNorm that includes all drugs available for prescription in the United States. The Current Prescribable subset also includes over-the-counter drugs.
Concept Description:
Product containing precisely everolimus 250 microgram/1 each conventional release oral tablet (clinical drug) - Description of concept identifier
Term Type (TTY):
FN - Term type in source with name and description
Term Type Name:
Full form of descriptor - Name of term type in source
Term Type Description:
- Description of term type in source
Code:
447132004 - "Most useful" source asserted identifier. If the source vocabulary has more than one identifier, or a RxNorm-generated source entry identifier. (if the source vocabulary has none.)
Suppress Flag:
N
Suppressible flag. Values = N, O, Y, or E. N - not suppressible. O - Specific individual names (atoms) set as Obsolete because the name is no longer provided by the original source. Y - Suppressed by RxNorm editor. E - unquantified, non-prescribable drug with related quantified, prescribable drugs. NLM strongly recommends that users not alter editor-assigned suppressibility.
CVF:
- Content view flag. RxNorm includes one value, '4096', to denote inclusion in the Current Prescribable Content subset. All rows with CVF='4096' can be found in the subset.
Source:
SNOMEDCT_US - Concept source abbreviation
Source Name:
US Edition of SNOMED CT - The official name for a source
Source Version:
2024_01_01 - The source version
Source Date:
March 04, 2024 - RxNorm data last updated
Source License Contact:
National Library Of Medicine
NLM is a Charter Member of SNOMED International on behalf of the U.S.
National Library of Medicine
8600 Rockville Pike

Bethesda
MD
United States
20894
1-888-FIND-NLM (1-888-346-3656)

https://support.nlm.nih.gov/support/create-case/
- The source license contact information
Source Content Contact:
National Library Of Medicine
NLM is a Charter Member of SNOMED International on behalf of the U.S.
National Library Of Medicine
8600 Rockville Pike

Bethesda
MD
United States
20894
1-888-FIND-NLM (1-888-346-3656)

https://support.nlm.nih.gov/support/create-case/
- The source content contact information
Source Short Name:
US Edition of SNOMED CT - The short name of a source as used by the NLM Knowledge Source Server

* This product uses publicly available data courtesy of the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Patient Education

Everolimus


Everolimus (Afinitor) is used to treat advanced renal cell carcinoma (RCC; cancer that begins in the kidneys) that has already been treated unsuccessfully with other medications. Everolimus (Afinitor) is also used to treat a certain type of advanced breast cancer that has already been treated with at least one other medication. Everolimus (Afinitor) is also used to treat a certain type of cancer of the pancreas, stomach, intestines, or lungs that has spread or progressed and that cannot be treated with surgery. Everolimus (Afinitor) is also used to treat kidney tumors in people with tuberous sclerosis complex (TSC; a genetic condition that causes tumors to grow in many organs). Everolimus (Afinitor and Afinitor Disperz) is also used to treat subependymal giant cell astrocytoma (SEGA; a type of brain tumor) in adults and children 1 year of age and older who have TSC. Everolimus (Afinitor Disperz) is also used along with other medications to treat certain types of seizures in adults and children 2 years of age and older who have TSC. Everolimus (Zortress) is used with other medications to prevent transplant rejection (attack of the transplanted organ by the immune system of the person who received the organ) in certain adults who have received kidney transplants. Everolimus is in a class of medications called kinase inhibitors. Everolimus treats cancer by stopping cancer cells from reproducing and by decreasing blood supply to the cancer cells. Everolimus prevents transplant rejection by decreasing the activity of the immune system.
[Learn More]


Cancer Chemotherapy


Normally, your cells grow and die in a controlled way. Cancer cells keep growing without control. Chemotherapy is drug therapy for cancer. It works by killing the cancer cells, stopping them from spreading, or slowing their growth. However, it can also harm healthy cells, which causes side effects.

You may have a lot of side effects, some, or none at all. It depends on the type and amount of chemotherapy you get and how your body reacts. Some common side effects are fatigue, nausea, vomiting, pain, and hair loss. There are ways to prevent or control some side effects. Talk with your health care provider about how to manage them. Healthy cells usually recover after chemotherapy is over, so most side effects gradually go away.

Your treatment plan will depend on the cancer type, the chemotherapy drugs used, the treatment goal, and how your body responds. Chemotherapy may be given alone or with other treatments. You may get treatment every day, every week, or every month. You may have breaks between treatments so that your body has a chance to build new healthy cells. You might take the drugs by mouth, in a shot, as a cream, or intravenously (by IV).

NIH: National Cancer Institute


[Learn More]


* Please review the disclaimer below.